+41 91 682 20 40 info@elixi-int.com
Niraparib (ZEJULA)

Niraparib (ZEJULA)

  On March 27, 2017 , the U.S. Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer…

Read More